UNDERSTANDING DYNAMICS IN THIN-FILM SPHERICAL CRYSTALLIZATION OF ACTIVE PHARMACEUTICAL INGREDIENTS FROM MICROFLUIDIC EMULSION by ZHENG LU
UNDERSTANDING DYNAMICS IN THIN-FILM




B.ENG., National University of Singapore
A THESIS SUBMITTED FOR THE DEGREE OF
MASTER OF ENGINEERING IN CHEMICAL AND
BIOMOLECULAR ENGINEERING




My two years research experience in KhanLab is filled with rewarding learnings
and fond memories. Prof Khan, thank you for the opportunity to work in the lab.
I owe you a great deal just for that, and I mean it. You showed me what research
really is, and that to me, is more important than the knowledge and skills I
have acquired during my two year journey. I thank you for all your support and
understanding whenever I wanted to try something different, may it or may it
not be research related. Those experiences have definitely made a difference in
my life.
I am also thankful to have the opportunity to work with some extremely
talented people. Arpi, Reno, Abu, Eunice, and Wai Yew: it has been a true
pleasure to work with you guys and I learnt so much from every single one of
you. I thank you for all the experiment we did together, all the discussions we
had, all the ideas we shared and all the encouragement and friendship you have
offered me. Dr. Brian Crump, thank you very much for your invaluable input
and suggestions on our crystallization project. Swee Kun, your presence in the
lab has been a great support and help. I thank you for the energy and laughter
you have brought me. Pravien, thank you for always being there to listen and
look out for me. I am also grateful for all your suggestions and advices on
research. KhanLab has been a wonderful family to me and I thank Sandra,
Barbara, Prasanna, Zahra, Yulia and Cathy for all the gatherings and fun we had
together.
I want to thank my friends in Singapore, especially Zhang Han and Julia, for
always being there during my ups and downs. The journey will not be the same
without people who walked in and out of my life in the past two years. I am
grateful for the joy and pain they have brought me.
Finally, I gratefully thank my parents, aunt and grandma, for all their love
and support throughout my life. I won’t be here without them.
3
Contents
Acknowledgements . . . . . . . . . . . . . . . . . . . . . 3
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . 6
List of Figures . . . . . . . . . . . . . . . . . . . . . . . 7
List of Symbols . . . . . . . . . . . . . . . . . . . . . . . 9
Prologue . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1 Introduction 1
1.1 Pharmaceutical Manufacturing . . . . . . . . . . . . . . 1
1.2 Pharmaceutical Crystallization . . . . . . . . . . . . . . 2
1.2.1 Crystalline Form . . . . . . . . . . . . . . . . 2
1.2.2 Particle Size . . . . . . . . . . . . . . . . . . 3
1.2.3 Production of API Crystals with Enhanced Micromeritic
Properties . . . . . . . . . . . . . . . . . . . 3
1.3 Emulsion-based Crystallization . . . . . . . . . . . . . . 4
1.3.1 Spherical Agglomeration . . . . . . . . . . . . . 4
1.3.2 Quasi-Emulsion Solvent Diffusion . . . . . . . . . 5
1.3.3 Emulsion-based Spherical Crystallization by Evapora-
tion, Cooling or Anti-solvent Addition . . . . . . . 5
1.4 Microfluidics . . . . . . . . . . . . . . . . . . . . . 8
1.4.1 Droplet Microfluidics . . . . . . . . . . . . . . 9
1.4.2 Applications of Droplet Microfluidics for Particle Syn-
thesis . . . . . . . . . . . . . . . . . . . . . 10
1.4.3 Crystallization in Droplet-based Microfluidics . . . . 11
1.5 Thesis Statement . . . . . . . . . . . . . . . . . . . . 12
2 Experimental Section 15
2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . 15
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . 15
2.2.1 Assembly of Microfluidic Device . . . . . . . . . 17
4
3 Understanding Dynamics in Thin-Film Evapora-
tion of Microfluidic Emulsions for Spherical Crys-
tallization 18
3.1 Nucleation - Classical Nucleation Theory . . . . . . . . . 19
3.2 Crystal Growth - Spherulitic Growth . . . . . . . . . . . 23
3.2.1 Spherulitic Crystallization on a Unified Basis - A Phe-
nomenological Theory[64] . . . . . . . . . . . . 25
3.2.2 Phase-Field Theory to Model Spherulitic Crystalliza-
tion[62] . . . . . . . . . . . . . . . . . . . . 26
3.3 Dynamics and Morphological Outcomes - Experimental Studies
and Modeling . . . . . . . . . . . . . . . . . . . . . 28
3.3.1 Experimental Observations . . . . . . . . . . . . 29
3.3.2 Theory . . . . . . . . . . . . . . . . . . . . . 34
3.3.3 Discussion . . . . . . . . . . . . . . . . . . . 39
3.3.4 Concluding Remarks . . . . . . . . . . . . . . . 45
3.4 Advancing Crystallization ‘Front’ Phenomenon . . . . . . . 46
3.4.1 Experimental Observations . . . . . . . . . . . . 47
3.4.2 Cause - Edge Effect . . . . . . . . . . . . . . . 50
3.4.3 Concluding Remarks . . . . . . . . . . . . . . . 51
4 Future Directions 54
4.1 Scale Up - A Proof-of-Concept . . . . . . . . . . . . . . 54




1 Summary of morphological outcomes under various conditions 30
2 The calculated values of classical nucleation theory parameters 38
3 Comparison of simulated and experimental data at 65 ◦C . . . . 40
4 Summary of the model validation exercise . . . . . . . . . . . . 46
5 Summary of the experiment results of edge effect . . . . . . . . 53
6
List of Figures
1 Schematic explaining the differences between the three major
categories of emulsion-based crystallization . . . . . . . . . . . 6
2 Schematic of experimental setup. . . . . . . . . . . . . . . . . 16
3 Schematic and photograph of a capillary microfluidic device
used in our experiments. . . . . . . . . . . . . . . . . . . . . . 17
4 Schematic representation of the Gibbs energy changes as a func-
tion of forming cluster radius R in the classical nucleation theory. 21
5 Various spherulitic morphologies. . . . . . . . . . . . . . . . . 23
6 The fraction of Morphology I SAs at different droplet sizes and
shrinkage rates . . . . . . . . . . . . . . . . . . . . . . . . . . 31
7 Analysis of the droplet shrinkage process . . . . . . . . . . . . 32
8 Shrinkage rate as a function of film thickness . . . . . . . . . . 32
9 Conceptual diagram of SA morphology formation . . . . . . . 35
10 CNT parameter B as a function of temperature . . . . . . . . . 39
11 The competition between supersaturation and nucleation . . . . 41
12 The simulated effects of droplet size and shrinkage rate . . . . . 42
13 CNT parameter A as a function of temperature . . . . . . . . . 44
14 Shrinkage rate as a function of temperature . . . . . . . . . . . 44
15 The simulated effects of droplet size and shrinkage rate . . . . . 45
16 Advancing Crystallizing ‘front’ phenomenon - 0.5 mm . . . . . 48
17 Advancing Crystallizing ‘front’ phenomenon - 1 mm . . . . . . 49
18 Edge effect experimental demonstration . . . . . . . . . . . . . 50
19 Schematic presentation of the edge effect hypothesis . . . . . . 51
20 Schematic presentation of COMSOL model . . . . . . . . . . . 52
7
21 Plot of mass transfer flux ratio of center and edge droplets at
different film thicknesses . . . . . . . . . . . . . . . . . . . . . 52
22 Droplet density and its effect on the edge effect . . . . . . . . . 53
23 Film thickness and its effect on the edge effect . . . . . . . . . 53
24 Conceptual schematic of continuous crystallizer . . . . . . . . . 54
25 To-scale model of prototype with main dimensions indicated . . 55
26 SEM of SAs from the continuous crystallizer . . . . . . . . . . 55
27 Emulsion generation of lipophilic APIs - ROY . . . . . . . . . 57
28 Characterization of ROY SAs obtained . . . . . . . . . . . . . 58
8
List of Symbols
κ Nucleation rate per droplet (s−1)
σ Interfacial tension between nucleus and solution
χ Diffusivity ratio
a Activity
aS Activity at saturation
A Classical nucleation theory parameter A (m−3s−1)
B Classical nucleation theory parameter B
d Diameter (µm)
d′ Shrinkage rate (µm·s−1)
d0 Initial droplet diameter (µm)
dA Agglomerate diameter (µm)
dc Critical droplet diameter (µm)
dm Molecular diameter (nm)
Drot Rotational diffusivity (m2s−1)
Dtr Translational diffusivity (m2s−1)
fI Fraction of Morphology I SAs
he Effective film thickness (mm)
h f Continuous phase film thickness (mm)
J Nucleation rate (m−3s−1)
k Boltzmann constant (J·K−1)
nCr Solid density (of glycine) (kg·m−3)
P0 Probability of no nucleation observed in a droplet over time




ts Shrinkage time (s)
9
T Temperature/set temperature (◦C)
TCP Continuous phase temperature (◦C)




Since the introduction of aspirin in 1899, and more particularly since the ad-
vent of antibiotics in the 1940s, society has come to rely on the widespread
availability of therapeutic drugs at reasonable prices. However, the timeline for
drug development remains long, and the obstacles to success remain high along
the way. For drugs delivered to patients in crystalline form (more than ∼90 %
of all pharmaceutical products), the crystal form, size and shape of the active
pharmaceutical ingredients (APIs) have an important impact on their physical
properties, such as solubility, stability and reactivity, thus in turn, their bioavail-
ability. This is especially true for low-solubility compounds, where the rate-
limiting step in drug uptake may be the dissolution of the APIs in the gut. The
physical properties of the APIs are often controlled in the final step of down-
stream processing crystallization, which is used for separation, purification and
formulation of APIs.
In the pharmaceutical industry, large crystals of API are first produced for
facile filtration in the crystallization process. Subsequently, size reduction pro-
cesses of APIs are used to increase surface area and improve formulation disso-
lution properties. One possible process for size reduction is dry milling, where
particulates are grinded down to the desired size distribution. However, dry
milling is (i) time and labor intensive, and (ii) associated with additional prob-
lems such as dust explosion hazards and worker exposure to APIs. Moreover,
crystal morphology and polymorphs may change during dry milling, affecting
bioavailability of the API . Thus, the efficient production of API crystals of de-
sired size and polymorphic form is one of the primary challenges in downstream
processing of pharmaceutical products. A wide range of methods for produc-
tion of API crystals with selected polymorphic forms have been demonstrated,
among which emulsion-based crystallization appears to be an attractive platform
for simultaneous control over both polymorphism and crystal size/shape. It en-
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able an alternative route for downstream processing in pharmaceutical industry,
where steps of crystallization and size reduction can be performed simultane-
ously by a single step. Furthermore, the achieved spherical shape can lead to
better downstream processability, in terms of flowability, compressibility, and
compactibility. Most of the studies on emulsion-based crystallization platforms
are conducted in stirred vessels, with a trial and error approach to investigat-
ing the effects of process parameters. Due to spatio-temporal inhomogeneity of
operating conditions in a stirred-batch crystallization process, directly relating
process parameters to particle properties becomes extremely difficult. However,
if we were to apply this technique in an industry setting, a clear experimental
understanding of spherical crystallization process is necessary.
Droplet microfluidics-enabled crystallization platforms provide exquisite con-
trol over process conditions, i.e. ensure minimal spatio-temporal differences.
Therefore, they are known for their ability to overcome challenges poseted by
inhomogeneous distribution of process parameters and capability to screen and
analyze nucleation and growth in crystallization processes. The advantages of
capillary microfluidics-based platform have been exploited in our recent demon-
stration in the production of glycine spherical agglomorates (SAs) with an un-
precedented control over crystal form, size and shape. In this platform, on-line
high-speed monitoring of the entire evaporative crystallization process, from
droplet shrinkage, nucleation, to the formation of spherical particles is made
possible.
In this project, building on the proof-of-concept demonstration, careful in-
vestigation of the entire crystallization process is carried out, with the aim to
strengthen the fundamental understanding of emulsion-based spherical crystal-
lization. Process parameters like droplet size, shrinkage rate, and temperature
are studied and found to play an important role in the final morphology of crys-
tals obtained. Their effects on spherical crystallization are investigated and cap-
tured by a theoretical model developed based on concepts drawn from classical
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nucleation theory. The model enables identification of crystallization conditions
that yield compactly packed spherical crystal agglomerates. The gained un-
derstanding makes it possible to employ advantages of microfluidics emulsion-
based crystallization (e.g. precise control over crystal size, shape and polymor-
phic form) to eliminate the need for costly downstream dry milling and grinding
in industry settings. It paves a way for designing novel continuous crystallizers




Manufacturing in the pharmaceutical industry accounts for almost a third of
the total costs, with expenses exceeding that of R&D[1], and therefore, draws
considerable attention for potential saving opportunities. Lean manufacturing
principles are claimed to generate up to $ 20–50 billion of savings per year for
pharmaceutical companies, by eliminating inefficiencies such as unnecessary
processing and inventory[2].
Pharmaceutical manufacturing plants for APIs are primarily batch-operated.
The nature of batch processing inherently leads to overproduction, such as in-
ventory buildup of intermediates, ultimately contributing to longer cycle times
and excess inventory stockpile. Such challenges can be addressed through the
concepts of continuous manufacturing. Continuous process has been proven
to be more economical, as compared to batch process, even for small processes.
Thus, dedicated continuous processes are strong candidates to replace batch pro-
cesses[3].
Pharmaceutical formulation process claims a significant fraction of the en-
ergy consumption of the whole manufacturing process.It is both labor and time
intensive. During a formulation process, APIs are blended with additives and
excipients, which is a crucial step in dictating the final bioperformance of the
product. Most APIs are produced in crystalline form, in poorly controlled crys-
tallization processes. These processes typically yield large crystals of irregular
shape and wide range of size distribution. Afterwards, the API crystals have to
undergo energy intensive and costly downstream processes, such as dry milling,
sieving, blending and granulation, to obtain desired composition and optimized
bioavailability, before tableting into final product[4].
Thus, there is a huge potential and great interest in the pharmaceutical indus-
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try, to significantly reduce the cost in manufacturing, through careful investiga-
tion in crystallization process that (i) lead to process understanding, (ii) improve
speed of development, and (iii) enable new technology platforms for continuous
production of API crystals.
1.2 Pharmaceutical Crystallization
Crystallization is often employed as a means to achieve separation, purifi-
cation to meet product requirement in the synthesis of fine chemicals and phar-
maceuticals. Specifically in pharmaceutical synthesis, crystallization is used for
two main purposes: (i) to separate and purify organic compounds and (ii) to
achieve desirable physical properties of APIs (e.g. flowability, compressibility,
and compactibility) for downstream processing and formulation. Most of the
APIs are delivered to patients in solid forms[5], for which physical properties
like crystalline form and particle size have significant impact on both bioperfor-
mance and downstream processability of the drugs.
1.2.1 Crystalline Form
Prior to a crystallization process design, a desired crystalline form needs to be
defined, often based on ease of downstream processing (e.g. filterability, stabil-
ity, flowability, manufacturability) or performance of final product (e.g. stabil-
ity, bioavailability, dissolution rate)[6], [7]. Different crystalline forms of APIs
may exhibit different physical properties, e.g. solubility, dissolution rate, melt-
ing point, chemical and physical stability, crystal habit and associated powder
properties (such as flowability, bulk density, compressibility etc.) and so on[6].
Many APIs can exist in different crystalline forms and polymorphism refers to
the occurrence of different crystalline forms of the same drug substance.
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1.2.2 Particle Size
Particle size of API affects product dissolution rate thus bioavailability of the
API. Product dissolution is a test to measure drug release profile (dissolved drug
content in the media as a function of time) and often correlated to exposure lev-
els in patients. A higher surface to volume ratio of crystals generally leads to a
faster dissolution rate. The smaller the crystals, the higher the surface to volume
ratio, thus the faster they dissolve[8]. Particle size also has an impact on powder
conveyance and mixing, which then further impact granulation. Granulation is a
unit operation to mix API crystals with excipients, lubricants and disintegrants,
before the final step of tableting. Moreover, particle size can affect the product
uniformity (the amount of API in each dose unit) and product appearance.
1.2.3 Production of API Crystals with Enhanced Micromeritic
Properties
Through co-formulation of API crystals with a higher amount of fillers ( ∼80
%), direct tableting of pharmaceutical products has been successfully demon-
strated in an industry scale. However, in order to save manufacturing cost and
improve patient compliance, it is desirable to achieve smaller dosage size, by
reducing the amount of fillers. Thus, it is of great interest for pharmaceutical
companies to produce API crystal particles with enhanced micromeritic prop-
erties (physical, chemical and pharmacologic properties of small API particles,
such as packability and flowability) in the absence of fillers or binders[9]. How-
ever, the use of crystallization for control over particle micromeritic properties
is highly dependent on process conditions, such as reactor design (geometry),
supersaturation profiles and choice of solvent, which often demonstrate spatio-
temporal inhomogeneity due to the nature of a large-scale batch process. Pro-
duction in large batch tanks generates crystalline materials with polydispersed
sizes (tens to hundreds of micrometers)[10], which need to go through a costly
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milling process to achieve desirable size distributions[11]. Therefore, one of the
primary challenges in pharmaceutical crystallization is how to efficiently pro-
duce API crystals of desired (uniform) crystalline form (polymorph) and size.
1.3 Emulsion-based Crystallization
Selective nucleation of desired polymorphs has been demonstrated by a wide
range of methods, such as seeded crystallization, additive, cooling of melts,
spray drying, mixed-solvents etc. [12] Among these methods, emulsion-based
crystallization, usually performed in stirred-vessels, is an attractive platform to
simultaneously control crystal polymorph and size. There are three different
methods for emulsion-based spherical crystallization of APIs: (i) fine crystals
are formed prior to emulsion generation, where an immiscible bridging liquid
(wetting agent) is used to aggregate the crystals, (ii) ”quasi-emulsions” are pre-
pared where crystallization occurs within the droplets via solvent-anti-solvent
counter diffusion, (iii) stable emulsions are produced first, subsequently, crys-
tallization occurs in the dispersed phase, and supersaturation is achieved by
evaporation, cooling or anti-solvent addition. A schematic explanation of all
three techniques are shown in Figure 1 below
1.3.1 Spherical Agglomeration
In this technique, small crystal seeds are pre-formed from solution, by cooling,
anti-solvent addition, or reactive crystallization. [13], [14] Afterwards, these
crystals are agglomerated by an immiscible bridging liquid which preferably
wets the crystal surface. One possible drawback of this system is its low yield
because of the drugs significant solubility in the crystallization solvent due to
co-solvency effect (when using anti-solvent for supersaturation generation) [15]
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1.3.2 Quasi-Emulsion Solvent Diffusion
There are three steps involved in the process: (i) formation of an emulsion (dis-
persed phase - drug dissolved in a good solvent, continuous phase - non-solvent
and emulsifier), (ii) creation of the supersaturation (through heat and mass trans-
fer in the system), and (iii) crystallization inside the droplets. The final outcome
of the process varies, from elongated crystals to spherical crystals, from hol-
low to full spherical agglomerates, which are determined by the competition
between three phenomena: mass transfer of solvent/non-solvent, heat transfer
and internal hydrodynamic circulation[16]. The word ”quasi” here implies the
short-lived nature of the emulsions, as compared to the stable ones.
1.3.3 Emulsion-based Spherical Crystallization by Evapora-
tion, Cooling or Anti-solvent Addition
In emulsion-based crystallization, API crystallization occurs in the dispersed
phase of emulsions (typically water-in-oil or oil-in-water), and supersaturation
is achieved by evaporation, cooling or anti-solvent addition.
In attempting to produce crystals with controlled size and shape, experi-
mental conditions need to be properly chosen, such that nucleation events are
confined to within the droplets[11]. Size of SAs formed can be varied by tuning
size of the emulsion droplets, by changing process conditions for emulsifica-
tion, the concentration and choice of surfactant and the ratio of the dispersed
and continuous phases[17]. As reported by Chadwick and co-workers, the rela-
tive solubility of API in the dispersed and continuous phases can affect the use
of emulsion droplets as crystallization environments[11]. There are three main
kinetic processes in an emulsion-based crystallization system: (i) nucleation in
the dispersed phase, (ii) nucleation in the continuous phase, and (iii) molecular
diffusion of solute from the dispersed to the continuous phase. To have pre-
cise control over crystal size and shape, it is desirable to choose the two liquid
5
Figure 1: Schematic explaining the differences between the three major cate-
gories of emulsion-based crystallization: a) spherical agglomeration, b) emul-
sion solvent diffusion or quasi-emulsion solvent diffusion, c) emulsion-based
spherical crystallization by evaporation, cooling or anti-solvent addition.
phases in a way which favors nucleation in dispersed droplets. However, to ob-
tain spherical agglomerates, confining nucleation events within a droplet alone
is not enough. Sjo¨stro¨m et al.[17] have reported that final morphology of crys-
tals formed is dependent on crystallization conditions and methods chosen. In
their study, crystallization by cooling generates needle-like crystals while evap-
orative crystallization generates spherical agglomerates. They have attributed
this observation to the lower supersaturations experienced in the cooling ex-
periment which increase the possibility of crystals growing in the continuous
phase, highlighting that a suitable choice of crystallization method is essential
for spherical crystallization from emulsion-based systems. Thus, given that the
crystalization method and process parameters are carefully and properly cho-
sen, crystallization in emulsion-based systems produces spherical crystals of
size distribution corresponding to that of emulsion droplets[11], which enabled
control over crystal size.
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The spherical agglomerates (SAs) produced have two main advantages: (i)
improved downstream processability[18] due to their spherical shape and (ii)
enhanced bioavailability due to the small size of the individual crystals that
make up the SAs[19], [20]. Besides enhanced properties of spherical crys-
tals obtained from the approach, as mentioned above, there are two more ad-
vantages of emulsion-based crystallization technique: (i) the impurities in the
system (if any) are captured in a small fraction of droplets, which prevents
contaminants from affecting the entire droplet population, thus increasing the
probability of homogeneous nucleation and improved product quality and (ii)
emulsion interfaces created enable selective nucleation of desired polymorphs
by a suitable choice of surface-active additives[21]–[23]. Skoda and van den
Tempel[21] have reported induced nucleation in aqueous triglycerides emul-
sions using emulsifiers whose molecular structure resemble that of the crys-
tallising triglyceride. Studies on interfacial crystallization have shown poly-
morphic selective nucleation of both organic and inorganic substrates, through
the use of close-packed monolayers[22], [24]. Such additives were chosen
based on two main criteria: (i) their molecular functionality and (ii) their hy-
drophobic/hydrophilic balance (to partition at water-oil interface) which subse-
quently enable the additives to possess the necessary stereochemistry to induce
the growth of fast-growing faces of the crystallization substrate[11]. Badrud-
doza et al. have demonstrated that functionalized silica nanoparticles (with suit-
able surface properties, here, surface charge) suspended in emulsion droplets,
may be used to obtain polymorphic control of API crystallization[23]. Thus,
emulsion-based spherical crystallization has the potential to offer control over
both crystal size/shape and polymorphic selection in a single step. The resul-
tant crystals of desired size/shape and crystalline form not only provide ease
of product formulation, but also eliminate costly downstream processes such as
dry milling and grinding.
However, most of the studies of emulsion-based crystallization platforms
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are conducted in stirred vessels with limited control over process parameters.
Thus, despite the potential advantages, crystal agglomerates obtained in these
processes still have a relatively wide size distribution (due to wide droplet size
distribution) and limited polymorphic control. Furthermore, to apply emulsion-
based crystallization in industry settings and maximize its potential in pharma-
ceutical manufacturing, a clear understanding of the process needs to be es-
tablished, especially process parameters and their impact on particle formation.
Several studies have been conducted in this area. Effects of experimental condi-
tions in an oil-in-water emulsion system adopting quasi-emulsion solvent diffu-
sion method for crystallization of APIs were investigated by Espitalier et al.[16].
Glycine crystallization outcomes were found dependent on the dimensions of
the two phase system (microemulsion, macroemulsion and lamellar phases)[25].
Roles of additives and process conditions in emulsion-based crystallization of
three hydrophilic APIs were studied by Chadwick et al., who obtained limited
control over selective nucleation of certain polymorphs[11]. Again, due to the
spatio-temporal inhomogeneity of operating conditions in a stirred-batch pro-
cess, relating process parameters to particle properties becomes extremely diffi-
cult, which results in limitations to in-depth understanding of particle formation
mechanisms.
1.4 Microfluidics
Microfluidics, as suggested by its name, refers to small volumes (typically
from nanoliter to attoliter) of fluid flowing in channels of a characteristic length
from tens to hundreds of micrometers[26], [27]. One obvious characteristic
of microfluidics is its small scale, which increases the specific surface area in
microfluidics by a few orders of magnitude, which, in turn, greatly improves ef-
ficiency for heat and mass transfer in microchannels. Another interesting char-
acteristic of microfluidics is laminar flow in channels[26]. In laminar flows,
mixing (mass transfer) is achieved by molecular diffusion and mixing time, τ ,
is characterized as τ ∼ L
2
D
where L is the diffusion length and D is diffusiv-
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ity. Thus, again, if L is greatly reduced, mixing time falls drastically. Besides
rapid mass and heat transfer in microfluidics, another advantage is its low vol-
ume consumption of reagents in individual experiments. Therefore, the cost of
expensive reagents used for process screening and the risks of handling dan-
gerous chemicals can be reduced, making microfluidics an appealing platform
for process analysis and method screening, in a less expensive and more ef-
ficient way. In terms of scaling up, microfluidics offers a unique concept of
numbering-up[28], which refers to increase production scale by employing du-
plicates of the same setup[29]. It may be easier as compared to the conventional
practice of volumetric scale-up, considering that the geometries stay the same,
therefore, so does the physics in the system. Aspects that are relevant to this the-
sis work, (i) droplet microfluidics, (ii) its applications for particle synthesis, and
(iii) online screening and monitoring of crystallization processes using droplet
microfluidics will be discussed in the following sections.
1.4.1 Droplet Microfluidics
Droplet-based microuidics, also called digital microfluidics, is one subcate-
gory of microfluidics[30], where droplets with controlled volume and composi-
tion are generated in microchannels, through competition between viscous drag
force and interfacial tension between immiscible phases. Different from single
phase flow systems, these droplets can be treated as independent microreactors
and analyzed individually[31]. By exploiting the advantage of a hydrodynamic
instability, microfluidics enables the formation of droplets in a controlled fash-
ion[32], where monodisperse droplets of dimensions from nanometer to mi-
crometer can be generated. As mentioned earlier, due to their small sizes, these
droplets have high surface to volume ratios thus possess high heat and mass
transfer efficiency, thereby allowing rapid transportation, mixing and reactions
within the droplets. As droplets are generated at up to kilohertz frequencies
while each acts as independent compartment, a large number of experiments
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can be performed in parallel. Thus, large amounts of data can be obtained at a
lower cost in a shorter time[33]. Therefore, droplet microfluidics is an attrac-
tive approach for library synthesis, process parameter investigation and high-
throughput screening by analyzing individual droplets[34].
Currently, there are two categories of droplet-based microfluidic devices: 2D
chips and 3D capillary microdevices. Typically, microchannels in 2D chip are
fabricated in two substrates: (i) silicon and glass (by photolithography and etch-
ing) and (ii) polymer materials, usually poly(dimethylsiloxane) (PDMS) (by soft
lithography)[35]. On the other hand, 3D capillary devices are built by putting
capillaries of small dimensions inside tubes, where the dispersed phase flows
in a capillary and the continuous phase flows in a tube. Inherently, wettability
of 3D capillary devices can be precisely modified by a surface reaction, usually
silanization[36]. 3D capillary devices are capable of producing structures[32]
where droplets generated are suspended in the continuous phase[37].
1.4.2 Applications of Droplet Microfluidics for Particle Syn-
thesis
Droplet-based microfluidic platforms for particle synthesis offer great advan-
tages, such as production of monodisperse particles with controlled size (nm to
µm range), unprecedented control over particle shape and structure, and a wide
range of droplet construction materials, from aqueous solution, gels, to poly-
mers[37]. Generally, the synthesis involves generation of monodisperse droplets
of desired shape (e.g. spheres, rods, cylinders) and certain material and a sub-
sequent droplet content solidifying process to form monodisperse particles[33].
A large body of literature exists on the production of advanced particles in
capillary-based microfluidic platforms. For instance, Nisisako and co-workers[38]
have demonstrated the preparation of monodisperse (coefficient of variation
less than ∼2 %) polymeric microspheres, where droplets contain monomers are
formed using a T-junction, which later, are polymerized in a curing step. They
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also reported that by adjusting Capillary number (Ca) of the system, droplet
size, which ultimately leads to particle size, can be tuned. Capillary num-
ber is defined as the ratio between force due to viscous drag and force due to
surface tension[32]. Other examples, including production of polymeric par-
ticles[39], [40], smart polymerosomes[41], and Janus particles[42] have been
demonstrated by capillary droplet-based microfluidic techniques as well. Other
than advanced polymer particles, production of crystalline solids with capil-
lary microfluidics has been reported as well. In McQuade group’s[43] pioneer-
ing work, core-shell organosilicon particles with uniform size and a highly or-
dered internal structure are generated. In their study, microcapsules are formed
from emulsion droplets through surface reactions between dispersed droplets
and continuous phase in a capillary microfluidic device.
1.4.3 Crystallization in Droplet-based Microfluidics
Microfluidics offer exquisite spatio-temporal control over operating conditions,
due to enhanced mass and heat transfer in the system as mentioned earlier,
which, when coupled with droplet microfluidics, where each droplet acts as
one independent compartment, thus one small batch vial, makes droplet-based
microfluidics a promising platform for operating parameter studies on crystal-
lization.
Crystallization in droplet-based microfluidics (chip-based) was first demon-
strated by Quake group[44] with protein crystallization, where experimental
parameters for crystallization are investigated. Exploiting the advantage of mi-
crofluidics in terms of faster mixing and less consumption volume, rapid screen-
ing of crystallization conditions is achieved with significantly less protein sam-
ple. Ismagilov and co-workers[45], building on Quake’s work, have developed
a method for high throughput screening of protein crystallization process condi-
tions. Afterwards, several studies employing chip-based platforms for study of
crystallization nucleation kinetics and process conditions have been carried out.
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It is worth noting that among them, a microfluidic platform for investigation of
the nucleation and growth of organic molecules is presented by Teychen and
Biscans[46].
Recently in our group[47], exploiting both the advantages of emulsion-based
crystallization and droplet-based microfluidics, direct production of glycine spher-
ical agglomerates (SAs) with an unprecedented uniformity, from microfluidics
emulsion droplets has been demonstrated. In this previous study, monodisperse
glycine-containing droplets (aqueous phase) suspended in the continuous (oil)
phase are generated and dispensed on a heated substrate and supersaturation is
generated by evaporation of the solvent, water. As water evaporates, droplets
shrink and supersaturation within droplets is generated. Thereafter, stochastic
nucleation in the droplet ensemble takes place, followed by spherulitic growth
and formation of glycine SAs. The system decouples droplet generation and
crystallization, which greatly reduces the risk of flow disruption and channel
clogging due to crystals formed within microchannels, which can be challenging
for on-chip crystallization experiments. Another added advantage of the system
is the capability to ensure spatio-temporal homogeneity of operating conditions
and conduct online high-speed monitoring of the entire SA formation process,
which can potentially enhance our understanding of spherical crystallization
process in emulsion-based systems, by directly relating process parameters to
particle formation mechanism and properties of particles produced.
1.5 Thesis Statement
To improve downstream processability of active pharmaceutical ingredient
(API) crystals, production of API spherical agglomerates (SAs) has attracted a
growing amount of attention. Recently, adopting a bottom-up design approach,
our group has demonstrated the production of glycine SAs with uniform size
and crystal form, through a capillary microfluidic-based platform, where simul-
taneously control over both crystal form and size/shape is achieved by a single
evaporative crystallization step, while potentially eliminating costly processes
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such as dry milling and grinding. Exploiting the advantages of the platform,
which enabled on-line high-speed monitoring of the entire particle formation
process, the final morphology of the SAs generated is found to be highly depen-
dent on process conditions chosen, such as dispensed droplet size, thickness of
film (shrinkage rate) and temperature. Since morphology of the SAs determines
their downstream properties and manufacturability, before the platform can be
scaled-up and applied in industry settings, clear understanding and further op-
timization of process conditions for SA production is of great importance and
interest.
In this project, building on the proof-of-concept demonstration, careful ob-
servations of the entire spherical crystallization process and detailed charac-
terization of crystallization outcomes under different operating conditions are
carried out, with the aim to establish a fundamental understanding of emulsion-
based crystallization process. Three process parameters: droplet size, shrinkage
rate (controlled by evaporation film thickness), and temperature are studied to
understand and delineate their effects on spherical crystallization from emul-
sions, thus identify a favourable crystallization condition regime for the produc-
tion of compactly packed spherical crystal agglomerates. Dynamics and mor-
phological outcomes of spherical agglomerates are presented, supported by a
theoretical model developed based on concepts drawn from classical nucleation
theory. It is found that a critical supersaturation (corresponding to a critical
droplet size) has to be reached before nucleation, in order to form complete
SAs. Thus, in the time required to reach the critical droplet size, if the proba-
bility of a nucleation event happening within a droplet remains low, probability
of complete SA formation is high. Generally, as indicated by experiment results
and the model, thinner films, smaller droplets and lower temperature are found
to give desirable crystallization outcomes of complete and compact SAs. In-
terestingly, an advancing crystallization ‘front’ phenomenon is observed in the
system, when droplet density is high (i.e. when droplets are closely packed),
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which causes severe secondary nucleation. These triggered secondary nucle-
ation events usually result in incomplete SAs or single crystals, which affect
product quality and consistency. These phenomena are hardly seen when the
film is thin and become more prominent with increasing film thickness. A mass
transfer model is developed and simulated to discuss and explain these phenom-
ena.
This gained understanding makes it possible to employ advantages of mi-
crofluidics emulsion-based crystallization for production of API spherical crys-
talline agglomerates in industry settings. It paves a way for designing novel




Glycine (>99%), dodecane (>99%), Span-20, Span-80, and Trichloro-
(1H,1H,2H,2H-perfluorooctyl)-silane (97%) were purchased from Sigma-Aldrich
and used as received. Ultrapure water (18.3 M) obtained using a Millipore
MilliQ purification system was used to prepare aqueous glycine solutions. Ster-
ile syringes (3 cc) and sterile single use needles (21 G 1.5”) were purchased
from Terumo Corporation, Japan. These syringes were used to dispense the
aqueous phase. The continuous phase was dispensed from 10 ml Hamilton
Gastight glass syringes. Syringe filters (0.45 µm) were purchased from Cole-
Parmer. Flat bottom glass Petri dishes (ID = 26 mm) made of borosilicate
were manufactured by HCS Scientific Chemical Pte Ltd, then silanized us-
ing 1H,1H,2H,2H-Perfluorooctyltriethoxysilane (98%) purchased from Sigma-
Aldrich. After silanization, the Petri dishes were used for sample collection
and as a crystallization platform. Dodecane was used as a continuous phase
(CP) with a 2% (w/w) surfactant mixture consisting of 70% Span-20 and 30%
Span-80 (w/w). The dispersed phase (DP) was a glycine solution saturated at
room temperature (24±1 ◦C); therefore the glycine content was approximately
25.4±0.5 g glycine/100 g water[25]. All solutions were filtered through a 0.45
µm syringe filter twice before each experiment.
2.2 Methods
Monodisperse emulsions were generated by glass capillary microfluidic de-
vices. One drop of the generated emulsion was dispensed directly into the glass
Petri dish which had a pre-dispensed layer of the CP (0.5-1.5 mm nominal thick-
ness), placed on a hotplate (Thermo Scientific CIMAREC) set between 45 and
85 ◦C. The temperature of the CP in the Petri dish was measured with a ther-
mometer (Lutron TM-914C with a thermocouple). Each experiment was re-
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peated at least three times, and each trial typically included at least 100 droplets.
Imaging of the process was performed with a high-speed digital camera (Basler
pI640) mounted onto a stereomicroscope (Leica MZ16). An Olympus LG-PS2
light source with a ring light was used for illumination. A silicon wafer was
placed under the glass Petri dish for improved contrast. Process imaging was al-
ways carried out at the center of the Petri dish to eliminate any potential menis-
cus effects. All experiments were imaged at 1 frame per second time resolution.
Microscopic image analysis was performed for droplet and SA size distribution,
nucleation, and morphology statistics. A field-emission scanning electron mi-
croscope (JEOL JSM-6700F) at 5 kV accelerating voltage was used to acquire
further structural information on the SAs. All samples were prepared on con-
ventional SEM stubs with carbon tape, and were coated with 10 nm of platinum
by sputter coating. A schematic of the experimental setup is provided in Figure
2.
Figure 2: Emulsion generation is performed in a concentric microfluidic glass
capillary setup, where a square capillary (ID=1 mm) houses a tapered round
capillary (OD= 1 mm). The two ends of the square capillary function as inlets
and the round capillary functions as a collection tube and outlet. The continu-
ous phase (CP) of dodecane (with dissolved surfactants) and a dispersed phase
(DP) of aqueous glycine are infused by syringe pumps into the square capil-
lary. The emulsions are collected in a heated glass Petri dish where evaporative
crystallization occurs.
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2.2.1 Assembly of Microfluidic Device
A schematic of the assembly and a photograph of the capillary microfluidic de-
vices used in our experiments are provided in Figure 3. Square (ID=1 mm)
and round (ID = 0.8 mm, OD = 1 mm) borosilicate capillaries were purchased
from VitroCom Inc. A micropipette puller (Sutter Instruments P-97) was used
to pull the round capillaries. Pulled capillaries were broken manually to pro-
duce tapered capillaries with different nozzle diameters. The capillaries were all
functionalized with Trichloro-(1H,1H,2H,2H-perfluorooctyl)-silane under vac-
uum for 8 hours in order to render their surfaces hydrophobic. Teflon tubing
(VICI, OD = 1/16 in, ID = 0.1 in) was used to connect the capillary device to
the syringes containing the continuous and dispersed phases (CP and DP, respec-
tively). The same were used as outlets. Silicone rubber transition tubes (Saint
Gobain, ID = 1 mm, OD = 3 mm) were used to connect the inlets to the square
capillaries. Fittings were purchased from Upchurch Scientific. DEVCON 5 min
Epoxy was used to seal the connection between the square capillaries and the
transition tubes.
Figure 3: A tapered round capillary (OD=1 mm) is inserted into a square cap-
illary (ID=1 mm). The two ends of the square capillary function as inlets, and
the round capillary functions as a collection tube/outlet. Silicone rubber transi-
tion tubes are used to connect the capillaries to the standard Teflon microfluidic
tubing connected to the syringe pumps (not shown on figure).
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3 Understanding Dynamics in Thin-Film Evapo-
ration of Microfluidic Emulsions for Spherical
Crystallization
As mentioned in Chapter 1, we have demonstrated a capillary microfluidics-
based platform, which combines microfluidics droplet generation and thin film
evaporation, for the production of glycine SAs with an unprecedented unifor-
mity, via a mechanism called spherulitic growth. However, we have noticed that
process conditions, such as droplet size, shrinkage rate and temperature play an
important role in the final crystal morphology. There were cases where single
crystals or incomplete SAs (Morphology II) were produced from the system,
instead of desirable, compactly packed complete SAs (Morphology I). In this
chapter, further investigation of the process was carried out in order to identify
a favorable regime for success production of desirable SAs. Before going into
the details, it is crucial that we have a basic understanding on crystallization
mechanism in the system.
Crystallization from solution can be considered as a phase change, in which
short or long range ordered molecules in a fixed lattice arrangement form a solid
phase from a solution. Final outcome of this complex process is determined by
the interplay of thermodynamics and kinetics. Although the solid phase stability
is governed by thermodynamics, if a metastable domain is established, the ki-
netic pathways will take over to determine crystal form created and life-span of
the form[48], [49]. Classically, crystallization is considered as a two-step pro-
cess: (i) nucleation, initiated by molecular aggregation, which then leads to the
formation of the smallest possible units with defined crystal lattice (nuclei)[48]
and a new solid phase and (ii) crystal growth, where the nuclei formed grow
larger through the addition of solute molecules[50]. In this thesis, classical nu-
cleation theory is adopted to model nucleation kinetics. Spherulitic growth is
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identified as the formation mechanism of SAs[47]. Thus, in the following sec-
tions, details of these two theories will be discussed.
3.1 Nucleation - Classical Nucleation Theory
As mentioned earlier, crystal nucleation from solutions involves molecular
aggregation in the supersaturated solution into organized clusters, creating a
surface that separates them from the environment[51]. Nucleation can be ei-
ther homogeneous or surface catalyzed. Due to random impurities in solutions,
which might induce nucleation, homogeneous nucleation seldom occurs in vol-
umes greater than 100 µL. Surface catalyzed nucleation can be promoted by sur-
faces of the crystallizing solute (secondary nucleation) or a surface/interface of
different composition than the solute (heterogeneous nucleation) which induce
nucleation by decreasing the energy barrier for nuclei formation[48]. Although
in practice, scenarios involving heterogeneous and/or secondary nucleation are
more commonly encountered, homogeneous nucleation forms the basis for clas-
sical nucleation theory (CNT)[51]. According to Ruckenstein and Djikaev[52],
W = X f in+Xin (3.1)
where
W is the reversible work of formation of a new-phase particle
X f in is the magnitudes of the appropriate thermodynamic potential X of the
system in its final (”mother phase + new-phase particle”) state
Xin is the magnitudes of the appropriate thermodynamic potential X of the
system in its initial states (”mother phase”)
The appropriate thermodynamic potential X in Eqn 3.1 has to be either the
Helmholtz free energy F (constant N, V , T ), or the Gibbs free energy G (con-
stant N, P, T ), or the grand thermodynamic potential Ω (constant µ , V , and T ),
determined by the conditions under which the phase transition takes place, with
N the number of molecules, V the total volume, T the temperature, P the pres-
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sure and µ the chemical potential. Ruckenstein and Djikaev[52] have pointed
out that in the thermodynamic limit, the expression for the work W has a general
form regardless of the thermodynamic potential X chosen.
W =Wv+Ws (3.2)
where Wv is volume contribution of the reversible work of formation of a new-
phase particle and Ws is surface contribution of the reversible work of formation
of a new-phase particle. The volume contribution Wv is always negative since
the new-phase particle is stable and has a lower free energy per unit volume
than the mother phase (metastable). The surface contribution Ws is, on the con-
trary, always positive[52]. Molecules on the surface feel less attraction from
their neighbouring molecules than those in the interior of the bulk phase, be-
cause surface molecules are not surrounded by as many neighbouring molecules
as the interior bulk phase molecules are. Weaker attraction caused by surface
molecules leads to less negative free energy, so surface formation causes the free
energy of the system to increase[53]. CNT is based on the changes in Gibbs free
energy, 4G, associated with the formation of a precipitate in a supersaturated
solid solution. According to CNT, the free energy change (4Gtotal) for a cluster
undergoing a phase transition, in the case of spherical precipitates of radius R,
is given by[54]:





4Gvolume is a volume free energy term that proportional to the cube of the
radius and favours aggregation of molecules (4Gvolume is negative)
4Gsur f ace is a surface free energy term that proportional to the square radius
of the cluster and favours the dissolution of molecular clusters (4Gsur f ace is
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positive)
4g is the driving force for precipitation per unit volume
γ is the specific interfacial energy
When radius R is small, the positive surface energy will dominate, and fur-
ther increment of R leads to energy increment of the system. Thus the cluster
formed tends to dissolve instead of grow. Eventually, the cluster attains the criti-
cal size (R= Rc) at which the total free energy of the cluster attains a maximum,
which corresponds to the activation free energy of nucleation 4G∗. Therefore,
in order to overcome the free energy barrier, supersaturation is required. Af-
ter this stage, the cluster becomes viable and is termed a nucleus, as further
growth of the cluster reduces the system energy thus crystal growth becomes
favorable[51].
Figure 4: Schematic representation of the Gibbs energy changes as a function of
forming cluster radius R in the classical nucleation theory. Figure adapted from
work published by Perez and Acevedo-Reyes[54]
In the area of crystallization kinetics, Volmer and Weber[55] proposed the








With JVW being nucleation rate (i.e. number of nuclei formed per unit volume
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unit time);4G∗ being the activation free energy of nucleation at the critical size
R∗; kB being the Boltzmann constant and T being temperature. Later, Becker
and Dring[56] and Zeldovich[57] investigated in the kinetic nature of this pre-
factor in Eqn 3.5, and came up with an expression of the nucleation rate as







Where β ∗ is the condensation rate of solute atoms in a cluster of critical size R∗
and N0 is the number of nucleation site per unit volume and Z is the Zeldovich
factor[54]. Nucleation rate in a supersaturated solution depends on chemical








Where J is the rate of nucleation in m−3s−1, A is a temperature dependent pre-
exponential factor (also in m−3s−1), B is a dimensionless kinetic barrier term
that depends on temperature and molecular properties and S is supersaturation,
defined as a/as where a is the actual activity of the solute, and as is the activity
of the solute at saturation[58], [59].
CNT has its own limitations. Capillary approximation, whereby the cluster
of a stable phase is assumed to have the same uniform physical-chemical proper-
ties (surface tension, density, etc.) as the bulk phase, is adopted for the thermo-
dynamics of nucleation in CNT[58]. This approximation greatly enhances the
simplicity of thermodynamics and kinetics of the system. However, it is also
believed to cause discrepancies for nucleation rate between theoretical predic-
tions and experimental data. The weakest point of this approximation is the use
of the macroscopic surface tension for the thermodynamic treatment of small
new-phase particles[52].
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3.2 Crystal Growth - Spherulitic Growth
Crystal growth refers to the process where nuclei grow larger through the
addition of solute molecules to the crystal lattice. Crystal growth is a multi-
step process[60], [61], which includes (i) transport of a growth unit (a single
molecule, atom, ion, or cluster) from or through the bulk solution to an impinge-
ment site, which is not necessarily the final growth site (i.e. site of incorporation
into the crystal), (ii) adsorption of the growth unit at the impingement site, (iii)
diffusion of the growth units from the impingement site to a growth site, and
(iv) incorporation into the crystal lattice. The relative importance of each step
depends on the surface structure of the crystals and the properties of the solu-
tion[51]. In most examples of crystal growth one finds that, after attaining stable
size, a typical primary nucleus grows into a crystallite having a discrete crystal-
lographic orientation. Generally speaking, this continues to develop as a single
crystal until it impinges either upon external boundaries or upon other similar
crystallites advancing from neighboring nuclei.
Figure 5: Various spherulitic morphologies.[62]
However, in certain systems, the primary nuclei are found incapable of
such development, giving rise instead to a more complicated structure of the
kind shown in Figure 5. This consists of a radiating array of crystalline fibers
and forms polycrystalline spherulites. Spherulites refer to polycrystalline ag-
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gregates, as opposed to single crystals, with an approximately radial symme-
try[63]. They are termed spherulites due to their large-scale average spherical
shape. Spherulites are ubiquitous in solids formed under highly nonequilib-
rium conditions[64]. Satisfactory understanding of the factors which lead to
and control spherulitic crystallization is a long standing problem in the field of
crystal growth[64]. There are pronounced similarities between spherulitic crys-
tallization in a wide range of substances - organic and inorganic, polymeric and
non-polymeric[62]–[64], which suggests the agency of certain mechanisms of
crystal growth which are (i) effective in spherulite-forming systems only and (ii)
common to all of these materials regardless of their unrelated physical proper-
ties. Thus, no matter what mechanism it may be, it cannot be too closely related
to molecular characteristics on the species involved. Therefore, there should be
a unified basis to account for mechanisms of spherulitic crystallization. Close
inspection reveals that in spherulites, the fibers branch in a manner which, un-
like dendritic branching, is noncrystallographic. By noncrystallographic, two
aspects are implied: (i) observed angles of branching are not simply related to
the geometry of the crystal lattice and (ii) the crystallographic orientation of a
parent fiber is not preserved in its daughter fibers (”small-angle branching”).
When first formed, spherulites consist of fibers or fibrils separated to a greater
or lesser degree from one another by layers of uncrystallized melt until the ra-
dial growth of the spherulites is complete. Afterwards, depending on the nature
of the system and experimental conditions used, the layers of melt either remain
uncrystallized indefinitely or they crystallize slowly to fill in the overall struc-
ture[64]. Now, with these observations in mind, we will look at two important
theories on spherulitic growth mechanisms.
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3.2.1 Spherulitic Crystallization on a Unified Basis - A Phe-
nomenological Theory[64]
This theory developed by Keith and Padden concerns mainly with spherulitic
crystallization from melts of relatively high viscosity in an impure system. They
proposed two specific requirements for spherulitic crystallization: (i) Condi-
tions must be favorable for the formation of crystals with a fibrous habit and
(ii) Fibers formed must be capable of noncrystallographic ”small angle branch-
ing”, where the crystallographic orientation of a parent fiber is not preserved
in its daughter fibers More appropriately, the branching can be described as a
splitting in which two different daughter fibers emerge from the tip of a parent
fiber at an arbitrary but usually small angle. Impurities play a crucial role in
promoting a fibrous habit in spherulitic crystallization. The theory assumes that
during crystal growth, impurities are segregated from the crystal, thus forming
a boundary-layer ahead of the solidification front. Once impurities exist in a
melt, the crystallization front advance rate no longer depends on the diffusion
of latent heat alone, instead, on an interplay of heat transport and the diffusion
of impurity. The growing crystal rejects impurity preferentially thus the con-
centration of impurity on the liquid side of the interface builds up. Unless the
crystallizing melt is stirred vigorously, an impurity rich layer will form at the
interface in the liquid. Such a layer probably plays an important role in promot-
ing a fibrous habit in spherulitic crystallization. Next, to elaborate on the ”small






Where D is the impurity diffusion coefficient, v is the a priori arbitrary velocity
of the solidification front. Fiber size scales with δ . As δ decreases, there is
a higher chance that one of the larger singularities at the shoulder of a grow-
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ing fiber is of sufficient size that, with further growth, it becomes a persistent
surface feature. If this new growth has a crystallographic orientation which de-
viates slightly from that of the parent fiber, it gives rise ultimately to a new
fiber which diverges from the original. Thus, one initial fiber (parent fiber) has
split into two fibers (daughter fibers), each about δ in width and each growing
along the same preferred crystal axis but misaligned slightly with respect to the
other. As δ decreases further, the probability of such an occurrence increases
correspondingly. When δ is very small, almost any island of surface disorder
becomes a possible source of noncrystallographic branching[63], [64].
Keith and Padden also have specified several properties of spherulites:
(i) Under isothermal conditions crystals grow at constant radial rate in al-
most all cases.
(ii) The most plausible interpretation of this constant growth rate is that the
rate of spherulitic growth is not controlled by diffusion, but rather, by growth
front nucleation rate.
(iii) As temperatures of crystallization increases, the textures of spherulites
generally become coarser, where the fibers or fibrils have relatively large cross
sections.
3.2.2 Phase-Field Theory to Model Spherulitic Crystalliza-
tion[62]
The theory of Keith and Padden is semi-quantitative and only applies to impure
systems. Gra´na´sy et al. have simulated spherulitic growth (Growth front nucle-
ation) phenomenon in highly non-equilibrium systems utilizing phase-field the-
ory. As compared to the theory proposed by Keith and Padden, their work can be
extended to pure systems while providing a more quantitative perspective. Ac-
cording to Gra´na´sy and co-workers, polycrystalline growth in spherulitic crys-
tallization (growth front nucleation) can originate from the quenching of orien-
tational defects, arising from either static heterogeneities impurities or dynamic
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heterogeneities intrinsic to highly non-equilibrium systems. In their simula-
tions, both types of disorder result in strikingly similar effects on crystalliza-
tion morphologies. Therefore the model implies that spherulitic crystallization
should occur both in highly impure and pure supercooled fluids. They have
proposed three possible mechanisms for spherulite formation[62]: (i) Due to
foreign particles. The presence of static heterogeneities impurities or molecular
defects and mass polydispersity in polymeric materials leads to a rejection of
these components from the growth front to form channels similar to those found
in eutectics; (ii) Trapping of orientation disorder due to reduced rotational diffu-
sional coefficient. Highly supercooled liquids are characterized by the presence
of long-lived dynamic heterogeneities. These heterogeneities can lead to the
formation of regions within the fluid which have either a much higher or much
lower mobility relative to a simple fluid in which particles exhibit Brownian
motion. Dynamic heterogeneity has a great influence on the transport properties
of these complex fluids, among which, the most relevant transport properties
for crystallization are shear viscosity and molecular mobility determined by the
translational and rotational diffusion coefficients. Rate of molecular translation
and rotation characterized by these coefficients directly controls the manner in
which molecules attach and align with the growing crystal. It is commonly
observed that in highly supercooled liquids the ratio of the rotational and trans-
lational diffusion coefficients decreases sharply by orders of magnitude, from
their nearly constant values at high temperature. Polycrystalline growth will
arise if the reorientation of molecules is slow relative to the interface propaga-
tion, as misoriented crystal regions at the liquid-solid interface have difficulty
aligning with the parent crystal; (iii) Noncrystallographic branching. More-
over, spherulitic growth has been observed in pure systems at low undercooling,
where neither the mechanism discussed in (i) and (ii) applies to explain poly-
crystalline growth. To account for this, a third mechanism - noncrystallographic
branching, which describes the formation of new crystalline branches that have
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a fixed misorientation relative to the mother crystal (and a grain boundary in
between), is incorporated. This mechanism is suggested by many experimental
observations. Building on Keith and Paddens theory, the phase-field theory by
Gra´na´sy et al. implies another important characteristic for spherulitic crystal-
lization: highly non-equilibrium conditions are favourable for spherulite forma-
tion in pure systems.
3.3 Dynamics and Morphological Outcomes - Ex-
perimental Studies and Modeling
Recently, we have demonstrated a capillary microfluidics-based platform for
the production of glycine SAs with an unprecedented uniformity, with the added
advantage of on-line high-speed monitoring of the entire process, from droplet
generation to shrinkage, nucleation, spherulitic crystal growth, and agglomerate
aging[47]. In this previous study, aqueous glycine-containing droplets gener-
ated from a capillary microfluidic device were first dispensed in thin oil films
on a heated substrate. Subsequently, water evaporation from the droplets led to
rapid shrinkage followed by stochastic nucleation in the droplet ensemble[65].
We observed that once a nucleation event occurred in these highly supersatu-
rated droplets, spherulitic growth proceeded rapidly with a characteristic linear
growth rate. As mentioned in the beginning of this chapter, we have noticed that
under different process conditions, the outcome of the final crystal morphology
could be different. There were cases where single crystals or incomplete SAs
(Morphology II) were produced from the system, instead of desirable, com-
pactly packed complete SAs (Morphology I). From these initial observations,
we anticipate that by changing processing parameters, such as droplet size, film
thickness and substrate temperature, we could potentially influence some or all
of these interacting processes, thus influencing the morphology of the SAs ob-
tained. Moreover, from a processing standpoint, it would be crucial to identify
regions of the multi-dimensional processing parameter space that yield SAs of a
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desired morphology. In order to understand in a more quantitative way how pro-
cess parameters influence the final crystal morphology outcomes, we exploit the
advantages of monodisperse microfluidic droplet populations and our ability to
monitor the crystallization process in individual droplets to gain further under-
standing of glycine SA formation in this system. Specifically, we investigate the
influence of droplet size, shrinkage rate and temperature on the crystallization
process.
3.3.1 Experimental Observations
Nine experiments - a 3x3 matrix of initial droplet diameters (d0) and film thick-
nesses (h f ) - were performed at a heating temperature of 65 ◦C in order to inves-
tigate the effect of droplet size and shrinkage rate (controlled by film thickness)
on the outcome of spherical crystallization in the droplet populations, and four
additional experiments were performed to shed light on the effect of temper-
ature, at 45, 55, 75, and 85 ◦C. Each experiment was repeated at least three
times, and each trial typically included at least 100 droplets. The experimental
conditions and the main outcome - the fraction of Morphology I SAs among the
crystallized droplet population - are summarized in Table 1, while the effects
of shrinkage rate and droplet size on the outcome of the process at a heating
temperature of 65 ◦C are given in Figure 6. As can be seen from the results, at a
fixed temperature, faster shrinkage rates (obtained in thinner films) and smaller
initial droplet sizes favor the formation of a higher fraction of Morphology I
SAs. On the other hand, this fraction exhibits an apparent maximum (at an in-
termediate temperature), on increasing temperature at fixed droplet size and film
thickness.
In order to understand these observations, the progression of the crystalliza-
tion process in the dispensed droplets was examined. Precise measurements of
droplet size were conducted from dispensing until the onset of crystallization
for at least 15 droplets per trial to determine how droplets shrank as water evap-
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Table 1: Summary of the experimental conditions used, along with shrinkage
times, shrinkage rates and the percentage of Morphology I SAs. #: experiment
label; d0 : initial droplet diameter; dA : SA diameter; T : heating temperature;
h f : film thickness; ts : shrinkage time; d′ : shrinkage rate (see text for further
elaboration on shrinkage); fI : observed fraction of Morphology I SAs among
the crystallized ensemble.
# d0 dA T h f ts d′ fI
µm µm ◦C mm s nm/s
1 53±3 39±2 65 0.5 62±2 220 0.99±0.00
2 53±3 39±2 65 1 1060±323 13 0.92±0.07
3 53±3 39±2 65 1.5 1637±459 8.6 0.61±0.24
4 85±10 62±7 65 0.5 88±9 260 0.96±0.01
5 85±10 62±7 65 1 2369±578 9.8 0.67±0.10
6 85±10 62±7 65 1.5 4074±1492 5.6 0.47±0.15
7 165±5 118±5 65 0.5 84±10 560 0.90±0.04
8 165±5 118±5 65 1 3130±1190 15 0.66±0.07
9 165±5 118±5 65 1.5 6055±2269 7.8 0.41±0.08
10 85±10 62±7 45 1 13500±900 1.7 0.48±0.05
11 85±10 62±7 55 1 7728±1883 3.0 0.64±0.07
12 85±10 62±7 75 1 2542±964 9.0 0.32±0.09
13 85±10 62±7 85 1 1500±180 15.0 0.28±0.06
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Figure 6: The fraction of Morphology I SAs obtained at T=65 ◦C under different
conditions. The thicker the film (which leads to a lower shrinkage rate), and the
larger the initial drop diameter, the lower the fraction of Morphology I (i.e.
complete) SAs.
orated (a visual example is provided in Figure 7). It was found that in all cases,
droplet diameter (d) decreased linearly with time (Figure 7b), as d(t) = d0−d′t
where d′ is the (measured) shrinkage rate, and d0 is the dispensed (initial) diam-
eter of the droplet. At a fixed temperature, shrinkage rate depends on the thick-
ness of the continuous phase film containing the droplets, and is determined
by the convective and diffusive transport of water through this film and into
the ambient environment. While nominally constant ambient conditions - room
temperature (∼24 ◦C) and relative humidity (∼57 %) - were maintained through-
out our experiments, complete elimination of environmental fluctuations, such
as those due to ambient air circulation, was not feasible. Therefore, to circum-
vent this challenge whilst retaining analytical rigor, measured shrinkage rates
are used in the discussions below, with the understanding that these relate in
a straightforward, quantifiable way to film thicknesses under highly controlled
processing conditions typical in pharmaceutical manufacturing. An example of
this relationship for our experiments is provided in Figure 8.
Next, we compare the diameter of the Morphology I SAs to the dispensed
31
Figure 7: a) An image sequence of the droplet shrinkage process with a film
thickness of 0.5 mm and T =65 ◦C. b) Droplet size measurements over time un-
der different film thickness conditions. c) Final droplet diameter (SA diameter)
as affected by the film height and initial droplet diameter for the 13 experiments.
Droplets shrink by roughly the same extent under all conditions: dA =0.73d0 .
Figure 8: An empirical relationship between the effective film thickness he ,
(defined as h f − d0, where h f is the dispensed film thickness, and d0 is the
initial droplet diameter) and the linear shrinkage rate d′ at T =65 ◦C for all nine
experiments at this temperature
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diameter of the corresponding droplets from which they were formed. Interest-
ingly, as shown in Figure 7c, it was found that under all conditions, droplets
shrank to roughly the same extent. In all cases, final SA diameter was ∼73 % of
the dispensed droplet diameter, implying, under the assumption that no glycine
leaves the shrinking droplets, that there is a limiting concentration (and there-
fore, a ’critical’ supersaturation Sc) beyond which shrinkage practically stops.
This phenomenon of a limiting supersaturation has also been reported in previ-
ous studies[11], [47] and can be explained by noting that in glycine solutions
at high supersaturation, the mutual diffusivity of water and glycine experiences
a dramatic drop[66], which restricts further diffusive mass transfer of water out
of the droplets. Therefore, further shrinkage of droplets is effectively inhibited,
leading to a limiting concentration (supersaturation). Moreover, it was also ob-
served that single crystals or incomplete SAs (i.e. Morphology II) tended to
crystallize when nucleation occurred in droplets before they reached this criti-
cal size. These observations imply that the attainment of the critical supersatu-
ration (Sc) corresponding to this critical size is necessary for spherulitic growth
to occur, which, in turn, can lead to the formation of complete SAs. Previous
studies also cite high supersaturation and severely limited diffusion as being
essential to the growth of spherulites. A comprehensive recent theoretical and
computational study by Gra´na´sy et al. proposed that at high concentrations, the
rotational and translational diffusivities of a solution are decoupled, and their
ratio (χ = Drot/Dtr) decreases sharply as supersaturation is increased, which
results in an enhancement of misoriented grain growth, leading to a spherical
shape at larger length scales[62]. This transition between single crystalline and
spherulitic growth of an increasing degree of branching (i.e. an increasingly
spherical shape) with an increasing supersaturation was also observed in exper-
imental studies[67]–[69]. As mentioned above, only SAs that grew into com-
plete, compact spheres were classified as ’spherulitic’ (Morphology I) and all
other morphologies were classified as Morphology II.
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Putting these pieces of evidence together, it can be hypothesized that droplet
size and shrinkage rate take part in an interplay of two related phenomena;
firstly, as droplets shrink and the concentration of glycine in a droplet increases,
supersaturation is achieved and increases over time, and secondly, for supersat-
uration S > 1, nucleation occurs in each droplet at a finite, non-zero rate J .
Therefore, as a droplet shrinks, there is a finite (and increasing) probability for a
nucleation event to occur in that droplet before it reaches the supersaturation Sc
required for spherulitic crystal growth. Thus, according to this line of reason-
ing, when a droplet reaches this critical supersaturation before the occurrence
of a nucleation event, a Morphology I SA is obtained. On the other hand, if a
nucleation event occurs before the critical supersaturation is reached within a
droplet, a Morphology II SA will be obtained, the exact morphology depending
on the conditions within the droplet. Figure 9a shows a schematic of this pic-
ture of crystallization in this microfluidic emulsion-based system, while 9b-d
display SEM images of the different possible particle morphologies. The ef-
fect of droplet size and shrinkage rate can now be explained with the arguments
presented above by noting that smaller shrinkage rates (for example by using
thicker oil films)lead to correspondingly slower rates of supersaturation genera-
tion, while larger droplet volumes are associated with a higher probability of a
nucleation event at a given supersaturation level.
3.3.2 Theory
Next, to model this process quantitatively, the following question has to be
asked: what is the probability of nucleation within a single droplet before it
reaches Sc, the critical supersaturation required for spherulitic growth? If, at the
time required for droplets to reach critical supersaturation (ts), the probability
of a nucleation event within a droplet is low (or conversely the probability of no
nucleation is high), a majority of Morphology I SAs can be expected to form
from the droplet population. In other words, if the above hypothesis describes
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Figure 9: a) Schematic of the SA formation process. There are two possible
outcomes: 1) Droplet reaches critical supersaturation before nucleation. This
leads to the formation of Mophology I SAs. Once formed, the SA might go
through an ’aging’ process, in which its surface transitions from a smooth to
a coarse structure, as seen in the previous chapter. 2) A nucleus forms within
the droplet before it reaches critical supersaturation, which leads to crystals of
Morphology II. b-d) SEM micrographs of different agglomerate morphologies
obtained from our experiments: b-c) ’smooth’ and ’coarse’ complete SAs; d)
single crystal.
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the process adequately, it can be expected that the probability of no nucleation
(P0) in a droplet at ts to corresponds, albeit roughly, to the fraction of Morphol-
ogy I SAs in a droplet population. A model to describe the stochastic nucleation
within small droplets with a time-varying supersaturation was formulated by
Goh et al.[70]. In this model, the evolution of Pn(t), the probability of n nucle-
ation events in a droplet, with time follows the following differential equations:
dP0
dt
=−κ(t)P0(t) P0(0) = 1 (3.9)
dPn
dt
=−κ(t)[(Pn−1(t)−Pn(t)] Pn(0) = 0 n = 1,2... (3.10)
where κ(t) is the nucleation rate in a single droplet, i. e.
κ(t) = J(t)V (t) (3.11)
Here, J is the nucleation rate (a function of S(t), the time-varying supersatura-
tion) and V is the volume of the droplet as a function of time. In this system,
Morphology I SAs grow rapidly in ∼0.1 s[47], and Morphology II crystals typ-
ically finish growing within a second; these growth times are far shorter than
typical shrinkage times of >100 s. Therefore, it can be assumed that only one
nucleation event occurs within a droplet - an assumption borne out in the ex-
periments. This, in turn, implies that P0(t) adequately describes the process.

















In order to compute P0(ts), t = 0 in the above integral is taken as the time
at which the shrinking droplet reaches S = 1, and ts is set to be equal to the
time when the droplet stops shrinking. This equality assumes that Sc is very
close to the final supersaturation attained by the droplets, which can be justi-
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fied by noting that as mentioned above - the reduction in diffusivity arresting
shrinkage[66] also facilitates spherulitic growth[62]. In this model, the mea-






where 0.73d0 is the average final size of the droplets (see discussion above) and
d′ is the linear shrinkage rate. To evaluate the integral in the exponent, classical








where A is a pre-exponential factor, described as the diffusion-limited rate of
nucleation (in this study A is a fitted parameter, see discussion below), S is the
supersaturation expressed as the ratio of the glycine activity relative to its value





where v is the molecular volume (assumed to be spherical for glycine with a
diameter of 0.53 nm [71]), σ is the interfacial tension between the nucleus and
the solution, k is the Boltzmann constant, and T is the absolute temperature.











where dm is the aforementioned molecular diameter, nCr =1575.3 g/L is the solid
density of glycine[75], and aS is expressed in units of g/L. The activity coeffi-
cients of glycine at various temperatures were obtained from AspenPlus VLE
simulations via the built-in UNIFAC model. Simulated activity data at 25 ◦C
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were validated with those reported by Na et al.[76]. The calculated values of
B and σ under the temperatures used in this study, and the polynomial fit used
in the calculations are presented in Table 2 and Figure 10 respectively.The sol-
ubility of glycine in water[25] and the density of aqueous glycine solutions[77]
were obtained from existing literature. By measuring the initial droplet size d0 ,





where d(t) = d0 − d′t. Knowing the initial concentration of glycine in the
droplets, V (t), and the simulated relationship between concentration and ac-
tivity, S(t), and hence, J(t) and P0(t) can be obtained. Ultimately, in order to
obtain P0(t) at a given temperature from this model, only two measured param-
eters, d0 (initial droplet diameter) and d′ (linear droplet shrinkage rate) need to
be specified. P0(t) was evaluated until ts for all experimental conditions.
Table 2: The calculated value of classical nucleation parameters under the tem-
peratures used in this study. #: experiment label (as seen in Table 1 and Table
4); T : heating temperature; TCP : measured continuous phase temperature;
σ : interfacial tension between the nucleus and the crystallizing solution; B :
dimensionless exponent B .
# T TCP σ B
◦C ◦C mJ/m2
10 45 39 12.8 2.69
V3 50 45 12.4 2.28
11, V1 55 48 12.2 2.13
V4 60 52 11.9 1.89
1-9, V5 65 59 11.5 1.59
V6 70 63 11.2 1.44
12, V2 75 68 11.0 1.27
13 85 78 10.5 1.03
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Figure 10: Parameter B as a function of continuous phase temperature along
with the polynomial fit used for modeling.
3.3.3 Discussion
The simulation results and the corresponding observed Morphology I fractions
for T = 65 ◦C are compared in Table 3. The value of the pre-exponential fac-
tor A = 2× 1012 m−3s−1 at T = 65 ◦C was obtained by nonlinear least square
regression performed in MATLAB on the results of all 9 experiments at this tem-
perature. The calculated trends from the model are generally in a good agree-
ment with experimental trends. Figure 11 shows three simulated P0(t) and S(t)
curves from three selected experimental conditions along with images from ex-
perimental runs. In the case shown in Figure 11a (and corresponding image in
Figure 11d), d′ is high, and d0 is small (experiment 1, Table 1). Here, P0(ts) is
very close to 1, which indicates that there is a low probability for a nucleation
event to occur before droplets reach critical supersaturation, leading to the ma-
jority of Morphology I SAs in this case. This is in good agreement with the
experimental observations, where ∼99% of the droplet population consists of
Morphology I SAs. Figure 11b and 11e shows a case where d′ is low and d0 is
large (experiment 9, Table 1). The calculated P0(ts) value of 0.33 indicates that
Morphology I SAs will be a minority in this sample, which is consistent with the
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experimental result of fI ∼0.4. In the simulation shown in Figure 11c, droplet
size is increased drastically (to ∼600 µm); thus P0 drops to nearly zero well be-
fore ts , which indicates that all droplets will likely nucleate before they reach Sc
and yield non-spherulitic, faceted crystals. This prediction is well borne out in
the corresponding experiment, shown in Figure 11f. Further validation comes
from the fact that the smaller satellite droplets co-generated with their larger
counterparts, in fact, yield the few Morphology I SAs that can be observed on
Figure 11f.
Table 3: Comparison of the simulated P0 (ts ) values (i.e. the probability of no
nucleation occurring within a droplet before it shrank to its limiting diameter)
to the fraction of Morphology I SAs at T=65 ◦C. The model accurately captures
the overall trends.
# d0 dA d′ P0(ts) fI
µm µm nm/s
1 53±3 39±2 220 1 0.99±0.00
2 53±3 39±2 13 0.99 0.92±0.07
3 53±3 39±2 8.6 0.99 0.61±0.24
4 85±10 62±7 260 1 0.96±0.01
5 85±10 62±7 9.8 0.93 0.67±0.10
6 85±10 62±7 5.6 0.89 0.47±0.15
7 165±5 118±5 560 0.99 0.90±0.04
8 165±5 118±5 15 0.56 0.66±0.07
9 165±5 118±5 7.8 0.33 0.41±0.08
These case studies show that our model describes the overall trends rather
accurately. There are, however, more subtle implications of the model that can
translate into a further understanding of this process. In the model, as mentioned
above, there are two parameters that determine P0(ts) at a given temperature d′
and d0 . Firstly, the effect of d′ is examined, where intuitively one can rea-
son that since no nucleation events in a droplet are required before reaching Sc
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Figure 11: The competition between time varying supersaturation S(t) and
P0(t), the probability of no nuclei forming within a droplet over time, for three
selected conditions. Data for P0(t)were obtained from the simulations described
in the text, while S(t) data were based on experimental measurements. If S
reaches the critical supersaturation required for spherulitic growth, Sc , before
the onset of nucleation, a certain fraction of Morphology I SAs form within the
ensemble. This fraction corresponds to the value of P0 at the time point when
S reaches Sc . a) and d) d0 =53 µm, h f =0.5 mm and T =65 ◦C; b) and e) d0
=165 µm, h f =1.5 mm and T =65 ◦C; c) and f) d0 =600 µm, h f =1 mm and
T =65 ◦C. The model accurately describes experimental trends. CSZ: critical
supersaturation zone.
, the larger the d′ , the better. However, increasing shrinkage rates also im-
ply decreasing shrinkage times, thus implying steeper rates of supersaturation,
and concomitantly larger nucleation rates at comparable times. The variation of
P0(ts) as a function of d′ at a fixed initial droplet size is therefore worth examin-
ing further, and model simulation results are shown in Figure 12a. These results
do in fact point to a nonlinear increase in P0(ts) with d′ , with a region of sharp
increase followed by a plateau. The simulations therefore recommend operation
at the cross-over point between the two regimes, beyond which there are dimin-
ishing returns on increased shrinkage rates, especially for the smaller droplet
sizes. Next, the effect of droplet size, d0 , is examined via a similar analysis.
At fixed shrinkage rate, the larger the droplet, the larger ts and V , but again,
J will be comparably smaller at each time point since S increases comparably
slowly. Results shown in Figure 12b demonstrate that the larger the droplet size,
the smaller P0(ts), and the lower the expected fraction of Morphology I agglom-
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erates from a corresponding experiment. Collectively, the above considerations
Figure 12: a) The simulated effects of initial droplet size d0 and linear shrinkage
rate d′ on P0(ts), the probability of no nucleation before shrinkage is complete;
b) The effect of droplet diameter at a constant shrinkage rate, all at T =65 ◦C.
It can be seen that at any given d0 , the largest shrinkage rate gives the highest
P0(ts) value (i.e. the highest expected fraction of Morphology I SAs in the en-
semble). Similarly, at any given shrinkage rate, as initial droplet size increases,
P0(ts) decreases, eventually reaching ∼0 beyond a certain critical diameter dc
(e.g. in the case of d′ =10 nm/s, the 280 µm droplets are above dc ).
imply that at a given shrinkage rate, there might exist a critical droplet diameter,
dc , above which no Morphology I SAs can be obtained from the system. To
calculate this value, P0(ts) can be simply set to ∼0 (e.g. 0.001) and for a cho-
sen d′ , dc can be obtained from the model. In fact, the choice of d0 for Figure
11f was based on these simulations, and led to an SA population that consisted
almost exclusively of Morphology II crystals. In principle, the same treatment
for a decreasing d′ could be used to obtain a critical value for shrinkage rate d′ ,
but reducing the rate of evaporation is generally unfavorable from a productivity
perspective. On the other hand, while increasing d′ is favorable for the produc-
tion of Morphology I SAs, the experimental apparatus used will necessarily set
upper limits on d′ . Therefore, one could imagine a scenario in which a solute
has a high enough nucleation rate before Sc is reached to completely preclude
spherulitic growth at droplet sizes achievable by microfluidic devices. Finally,
it is also noted that the generality of this model means that it can describe the
crystallization behavior of solutes in which, for example, the functional form of
J(S) is different from that used in Equation 3.14 above.
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The experimentally observed effect of temperature at a given film thickness
and initial droplet diameter is a more complex issue. The experimental results
in Table 1 (experiments 10-13) suggest an optimal intermediate temperature at
which the highest fraction of Morphology I SAs is produced under otherwise
identical conditions. In order to explain this trend, the behavior of the two pa-
rameters in the nucleation rate expression must be examined: while B can be
calculated in straightforward fashion as outlined above, A is a rather sensitive
parameter that is a complicated function of temperature and molecular proper-
ties[73]. In this study, A was fitted to the results of all experiments at h f =1
mm and d0 =85 µm (13). Knowing A(T ) now enables the prediction of P0(ts)
at any given point in the (d0 , d′ ) parameter space at a given temperature. Fig-
ure 15 shows illustrative simulated surfaces of P0(ts) as a function of d0 and d′
at three representative temperatures within the range studied. It is instructive
to observe that at each temperature, there exists a region on this map where
P0(ts) ∼1, adjacent to a fairly steep intermediate region, ultimately leading to
a domain where P0(ts)∼0. It would generally be desirable to operate a crystal-
lization process well within in the P0(ts)∼1 region. The most practical way to
achieve this is to use the highest possible shrinkage rate (and thus lowest practi-
cal film thickness) at a given temperature and droplet size. Next, to explain the
optimal temperature reported in Table 1, note that the shrinkage rate at a given
film thickness increases with temperature, and while film thickness is the tun-
able processing parameter, the shrinkage rate is what ultimately influences the
outcome of the process. If the outcomes of experiments conducted at h f =1 mm
and d0 =85 µm at different temperatures (#5, 10-13 in Table 1) are compared to
simulated P0(ts) values using a shrinkage-rate temperature relationship fitted to
the measured shrinkage rates (Figure 14), the experimentally observed trend is
recovered (Figure 15d).
Finally, the validity of the model was further tested in the following way.
Three SA sizes were selected as targets under two selected conditions of d0 and
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Figure 13: Experimentally derived log(A) values as a function of continuous
phase temperature along with the fitted quadratic curve that was used in the
modeling. This fit implies that the relationship is of the form A = A0 exp[ f (T )],
which is consistent with previous reports [59].
Figure 14: Experimentally measured shrinkage rates at various continuous
phase temperature along with the linear fit used in the simulations for Figure
15d.
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h f within the previously described range. Measured fI and simulated P0(ts) data
were compared to determine whether or not the model proved to be accurate in
predicting the superior processing conditions (i.e. which condition produced
the higher fraction of Morphology I SAs). The experimental conditions and the
results are presented in Table 4. It can be seen that the model provided correct
predictions in all three cases, even though all the experiments were performed
in the steep intermediate range of P0(ts) described above.
Figure 15: a-c) Simulated surface plots of P0(ts) in the two-dimensional d0
-d′ space, at a) T =50 ◦C, b) T =60 ◦C, and c) T =70 ◦C. Note the expan-
sion of the low P0(ts) region with increasing temperature. d) Simulated P0(ts)
compared to experimental results for d0 =85 µm and h f =1 mm at different
temperatures (shrinkage rate-temperature relationship used in the simulations
is provided in Figure 14). The model qualitatively captures the experimentally
observed trends.
3.3.4 Concluding Remarks
In conclusion, our experiments indicate that a smaller initial droplet diameter,
a higher linear shrinkage rate, and a lower temperature favor the formation of
complete SAs, while the opposite leads primarily to incomplete spherical ag-
45
Table 4: Summary of the validation exercise to test the predictive capability of
the model.
# d0 dA T h f d′ P0(ts) fI
µm µm ◦C mm nm/s
V1 73±5 53±4 55 0.8 4.7 0.98 0.91±0.03
V2 73±5 53±4 75 1.3 6.7 0.91 0.26±0.05
V3 110±8 81±6 60 0.6 31 0.98 0.94±0.03
V4 110±8 81±6 50 0.9 3.3 0.91 0.71±0.07
V5 157±9 110±7 65 0.8 13 0.87 0.78±0.05
V6 157±9 110±7 70 0.65 51 0.95 0.91±0.01
glomerates and faceted single crystals. We analyze our observations within the
framework of a simple physical model based on classical nucleation theory and
the theory of non-homogeneous Poisson processes, which accurately captures
the overall trends. According to this model, smaller droplets and faster shrink-
age rates (in thinner films) favor the formation of compact SAs at a given tem-
perature, and lower temperatures generally favor compact SA formation at a
fixed drop size and shrinkage rate, which is in line with our experimental obser-
vations.
3.4 Advancing Crystallization ‘Front’ Phenomenon
As discussed in Section 3.3, we conducted on-line high-speed monitoring
of the entire crystallization process, from shrinkage to nucleation, spherulitic
crystal growth, and aging and have developed a model to capture dynamics of
crystal morphology outcomes when only primary nucleation events are taking
into account. Interestingly, besides primary nucleation events, in our system we
have also seen an advancing crystallization ‘front’ phenomenon when droplet
density is high (i.e. when droplets are closely packed), which causes severe sec-
ondary nucleation. These triggered secondary nucleation events usually result
in incomplete spherulites or single crystals, which affect product quality and
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consistency. These phenomena are hardly seen when evaporation film thickness
is thin and become more prominent with increasing film thickness. In this sec-
tion, detailed observations, possible explanations and implications on choice of
process parameters are discussed.
3.4.1 Experimental Observations
Advancing crystallization ‘front’ phenomenon refers to the phenomenon where
droplets shrink faster (thus crystals form earlier) in certain regions of the crys-
tallization platform than other regions. When these early formed crystals get in
touch with the neighboring droplets that havent reached their critical size or su-
persaturation, they trigger their nucleation resulting in incomplete spherulites or
single crystals. These phenomena are only observed when droplets are closely
packed and more prominent in experiments where droplets shrinkage is slow
(under thicker films). To capture the advancing crystallization front phenomenon
in our system, we conducted a statistical analysis of the nucleation events hap-
pening across the entire crystallization platform. The field of view was divided
into 8 different regions, from left to right, and the number of nucleation events
occurring inside each region were counted at different time intervals. If at a
given time interval, nucleation events are scattered across the entire field of
view, most likely there is no advancing crystallization front phenomenon in the
process. On the other hand, if at a given time interval, nucleation events are
concentrated inside one or two regions and the crystallizing region is advancing
in one direction with time, it suggests the existence of advancing crystallization
front phenomenon. An example is provided using experimental data obtained
from crystallization of compactly packed (packing density ∼ 80%) droplet with
diameter of 60 µm at film thickness = (i) 0.5 mm and (ii) 1 mm, as shown in
Figure 16 and 17 respectively. It can be clearly seen that in the case of 1 mm
film thickness, advancing crystallization ‘front’ phenomenon exists.
47
Figure 16: An experimental observation of nucleation statistics at film thickness
= 0.5 mm. Time = 0 represents the first nucleation event in the ensemble.
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Figure 17: An experimental observation of nucleation statistics at film thickness
= 1 mm. Time = 0 represents the first nucleation event in the ensemble.
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3.4.2 Cause - Edge Effect
As mentioned earlier, the main cause of the advancing crystallization front phe-
nomenon is different droplet shrinkage rates in different regions of the crystal-
lization platform (glass petri dish), which then causes different nucleation rates
and severe secondary nucleation. Figure 18 clearly shows that at one side of the
petri dish, drops shrink faster than the other side and started crystallizing. Now
the question becomes why? We define droplet density as the area occupied by
droplets divided by total area in the field of view (a percentage). We noticed that
when droplet density is high (∼ 100%), the advancing crystallization front phe-
nomenon is observed. The droplets at the edge of the entire ensemble (which is
not fully surrounded by other droplets) shrink faster than the ones in the center
of the ensemble; these phenomena are hardly seen for thin evaporation films and
become more prominent with increasing film thickness.
Figure 18: (a) After dispensing (t = 0s), all droplets are of the same size. (b)
At time = 1670s, as they shrink, the ones at the edge become obviously smaller
than the inner ones and started crystallizing.
We hypothesis this could be due to the difference in mass transfer flux of
water out of the droplets (thus evaporation rate) between the center and edge
droplets of the ensemble. Droplets at the center will only have one mass trans-
fer direction while the edge droplets could possibly have two mass transfer flux
components, as indicated in Figure 19 below. Furthermore, when film is thin,
J1 will dominant and J2 is negligible, thus we will not see much of a difference
in center and edge droplet shrinkages. While film becomes thicker, J1 becomes
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smaller and eventually comparable with J2, thus droplets at the edge will shrink
faster than the center ones. We term this as edge effect. Next, to validate our
hypothesis, a mass transfer model is built in COMSOL software. For simplic-
ity, we assume the closely packed droplet ensemble to be a thin slab of water.
The geometry and boundary conditions used are shown in Figure 20. Fick’s
second law of diffusion was used to solve the model. Total fluxes at the cen-
ter and edge of the ensemble were obtained and can be decomposed into two
directions (J1 and J2) as in our hypothesis. Indeed we observe in the center,
J2 is almost negligible while at the edge, when film is thin, J2 is incomparable
with J1 and becomes more important with increasing film thickness. Ratios of
total mass transfer fluxes at the center and at the edge of the ensemble, α , are
plotted against time under different film thickness conditions (Figure 21), which
confirmed our hypothesis of edge effect.
Figure 19: An illustration on the hypothesis of different flux components: when
closely packed, droplets at the center and the edge of the ensemble have different
mass transfer fluxes. At the center, only one direction is possible while at the
edge, there are two possible fluxes.
3.4.3 Concluding Remarks
As shown in Figure 22, 23 and Table 5 below, droplet density and film thickness
are two important factors governing the edge effect. In order to optimize the
morphology outcomes from the system and avoid secondary nucleation, there
might be a limiting droplet density that we can use. Again, the thinner the film,
the less is the possibility that this advancing crystallizing front phenomenon will
occur.
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Figure 20: An illustration on the model geometry and boundary conditions
Figure 21: Plot of mass transfer flux ratio of center and edge droplets obtained
from the model at different film thicknesses. As can be seen, when film is thin,
the total mass transfer flux of droplets at the center and edge of the droplet
ensemble are almost identical. As the film becomes thicker, the center flux
becomes obviously smaller than the edge flux.
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Figure 22: (a) Droplet diameter = 60µm, film thickness = 1 mm. When droplet
density is high, severe edge effect takes place and product quality of crystals
obtained are low (b) Droplet diameter = 60µm, film thickness = 1 mm. When
droplet density is low, no edge effect is observed and product quality of crystals
are high
Figure 23: (a) Droplet diameter = 60µm, droplet density is high When film
thickness = 0.5 mm, no edge effect is observed and product quality of crystals
are high. (b) Droplet diameter = 60µm, droplet density is high. When film
thickness = 1 mm, severe edge effect takes place and product quality of crystals
obtained are low.
Table 5: Summary of the experiment results under different droplet densities
and film thicknesses.
# d0 T h f Droplet
Density
fI
µm ◦C mm %
1 60±5 65 0.5 74.3 0.99
2 60±5 65 1.0 99.9 0.21
3 60±5 65 1.0 14.5 0.91
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4 Future Directions
4.1 Scale Up - A Proof-of-Concept
With the gained understanding of dynamics and morphological outcomes
from the system, we are one step closer to employing advantages of emulsion-
based crystallization, such as precise control over crystal size, shape and poly-
morphic form in industry settings. This gained understanding paves a way for
designing a novel continuous crystallization reactor for industrial scale manu-
facturing of APIs. A conveyor belt prototype of a continuous crystallizer was
built as the first step towards scaling up (Figure 24 Figure 25).
Figure 24: A schematic of the continuous crystallizer. Emulsions are dispensed
on a heated conveyor belt, where evaporative crystallization take place, leading
to the formation of SAs. A scraper is used to collect the product.
The prototype has a production rate of 1 ∼ 10 g/day depending on process
parameters chosen. Preliminary results of the spherical agglomerates obtained
from the prototype are shown in Figure 26 and compared with the semi-batch
approach in the proof-of-concept demonstration[47]. As can be seen, there is
no qualitative difference between the SAs obtained from the semi-batch method
and those obtained from the prototype. Further optimization of the prototype is
required in the areas of (i) better control over film thickness on the belt and (ii)
better belt temperature and ambient humidity control during the crystallization
process.
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Figure 25: to-scale model of prototype with main dimensions indicated
Figure 26: Comparison of SEM images of 50 µm glycine SAs produced by the
prototype and the semi-batch method under different control temperatures: a)
35 ◦C, b) 55 ◦C, c) 75 ◦C. Left column: semi-batch SAs, right column: SAs
collected from the scraper. The scale bar is valid throughout a-c.
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4.2 Generalization to Lipophilic APIs
The work reported in this thesis on pharmaceutical crystal engineering for a
hydrophilic drug molecule (glycine) lent us rigorous understanding of the pro-
cess and enabled future scaling up for industrial applications, which is one pil-
lar of our ultimate goal: to build a pharmaceutical crystal engineering toolbox
where we will be able to generalize our method to engineer a wide range of
drug substrates with different properties, and eventually apply the technology
developed in an industrial setting. In the first step toward generalization, instead
of hydrophilic drugs, we focus on lipophilic drugs. We chose 5-methyl-2-[(2-
nitrophenyl)amino]-3-thiophenecarbonitrile (also known as ‘ROY’, due to the
characteristic color of its polymorphs) as our model API here. ROY has been a
challenging molecule to crystalize as it exhibits conformational polymorphism
and has 10 reported polymorphs[78].
We used the same method as our previous demonstration for emulsion gener-
ation and evaporative crystallization[47]. The only difference here is instead of
water-in-oil emulsions, we inverted the system to oil-in-water emulsions (Figure
27). ROY-DCM in water emulsions were generated from a microfluidic glass
capillary device and spherical agglomerates of ROY were obtained by evapora-
tive crystallization. As compared to the case of glycine, the ROY SAs are rela-
tively less monodisperse and irregular shaped (Figure 28). Optical microscopy
images of the ROY crystals indicate concomitant polymorphism and thus rather
poor control over polymorphic selection (Figure 28); DSC characterization fur-
ther confirms the concomitant occurrence of both YT04 and OP polymorphs.
Thus, our next step will be focusing on polymorphic selection in the system, to
obtain ROY spherical agglomerates with controlled polymorphism outcome.
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Figure 27: (a) Single emulsion generation of ROY-DCM solution at the tip of the
inner round glass capillary, of a microfluidic device operating at a flow focusing
configuration. Stereomicroscopic images of dispensed (b) ROY-DCM emulsion
droplets, and (c) Carbamazepine-DCM emulsions droplets.
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Figure 28: Optical [(a), (b)] and FESEM [(c), (d)] images of pure ROY (400
mg/mL) microparticles: a mixture of yellow, orange and brown colored particles
indicate the lack of polymorphic selectivity; (e) Differential scanning calorime-
try (DSC) profiles indicating concomitant polymorphism of YT04 and OP poly-
morphs of ROY for both thin (0.5 mm) and thick film (2 mm) conditions.
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5 Epilogue
In conclusion, in this thesis, building on the proof-of-concept demonstra-
tion, investigation of the entire spherical crystallization process and detailed
characterization of crystallization outcomes under different operating condi-
tions are carried out, with the aim to strengthen our fundamental understand-
ing of emulsion-based crystallization process. Specifically, process parame-
ters like droplet size, shrinkage rate (controlled by evaporation film thickness),
and temperature are studied to understand and delineate their effects on spher-
ical crystallization, thus identify crystallization conditions that yield compactly
packed spherical crystal agglomerates. Dynamics and morphological outcomes
of spherical agglomerates are presented, supported by a theoretical model de-
veloped based on concepts drawn from classical nucleation theory. It is found
that a critical supersaturation (corresponding to a critical droplet size) has to be
reached before nucleation, in order to form complete SAs. Generally, as indi-
cated by experiment results and the model, thinner films, smaller droplets and
lower temperature are found to give desirable crystallization outcomes of com-
plete and compact SAs. Interestingly, when droplet density and film thickness
is high, secondary nucleation can be observed in the system due to an advanc-
ing crystallization ‘front’ phenomenon. These triggered secondary nucleation
events usually result in incomplete SAs or single crystals, which affect prod-
uct quality and consistency. This gained understanding makes it possible to
employ advantages of microfluidics emulsion-based crystallization in industry
settings. It paves a way for designing a novel continuous crystallization reac-
tor for industrial scale manufacturing of APIs. It opens possibilities for future
development directions, including generalization of the process for the produc-
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